2QV Stock Chart & Stats
€2.94
€0.00(0.00%)
At close: 4:00 PM EDT
€2.94
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.86 - €3.78
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.13M
Enterprise Value€4.48
Total Cash (Recent Filing)€8.04M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,192,266
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.03Price Target Upside343.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt materially reduces solvency and interest-service risk for a clinical-stage biotech. With low leverage the company retains flexibility to fund R&D via equity or partnerships, improving resilience across funding cycles and lowering bankruptcy risk during multi-year trials.
Improving Burn TrendA material improvement in 2025 operating losses and cash burn signals better cost discipline and program prioritization. Sustained reductions in burn extend runway, reduce near-term financing pressure, and make the company a more credible partner for licensing or collaboration talks.
Clinical Biomarker ProgressDose-dependent improvements and AI-driven biomarker evidence in PSC support target engagement for nebokitug and strengthen the scientific rationale. Durable translational data enhances partnering and licensing prospects and materially de-risks the program versus candidates lacking mechanistic biomarkers.
Bears Say
Pre-revenue OperationsAbsent product revenue the company must rely on external financing or partnerships to sustain operations. This structural dependency increases dilution risk and constrains strategic options until clinical programs reach partnering or commercialization milestones.
Persistent Negative Cash FlowConsistent negative operating and free cash flow means ongoing financing is required to fund trials and corporate activities. Even with recent improvement, structural cash deficits leave the firm exposed to capital-market volatility and could delay programs if funding conditions tighten.
Eroding Equity BaseMaterial declines in equity and assets reflect cumulative losses and possible dilution, weakening the balance sheet's capacity to support borrowing, partnerships, or acquisitions. A smaller asset base raises long-term funding and negotiating fragility with potential collaborators.
Chemomab Therapeutics News
2QV FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was €2.86 and its highest was €3.78 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is €9.13M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 7 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on May 14, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.003.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -€0.003 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in DE:2QV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
2QV Stock 12 Month Forecast
Average Price Target
€13.03
▲(343.23% Upside)